Copy to clipboard 
MicroPort Orthopedics reported 1H23 orthopedic sales of $116.4 million, +8% compared to the first half of 2022.
The company’s efforts in expanding its channels in the EMEA region led to significant strength there, with mid-teens growth compared to the prior year. MicroPort’s Medial-Pivot Knee made further inroads in international markets, helping drive the company’s knee replacement sales.
MicroPort actively sought out secondary supply partners during the first half to mitigate future supply risks. The company received its first batch of components from those suppliers in July 2023, helping to reduce backorders significantly.
In its Chinese domestic market, the company drove growth greater than 50% driven by the implementation of volume-based procurement for joint replacement products and recovery in elective surgery demand. MicroPort is focused on reducing costs and increasing efficiency in its spine and trauma businesses as volume-based procurement tenders impact those segments.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. We estimate orthopedic sales and growth on an as-reported basis.
Orthopedic Sales by Segment
| 1H23 | 1H22 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $112.7 | $104.4 | $8.3 | 8% |
| Knees | $47.1 | $41.9 | $5.2 | 12.5% |
| Hips | $65.6 | $62.5 | $3.1 | 5% |
| Spine | $1.9 | $1.7 | $0.1 | 8% |
| Trauma | $1.8 | $1.6 | $0.2 | 11.6% |
| Total | $116.4 | $107.7 | $8.6 | 8% |
Orthopedic Sales by Geography
| 1H22 | 1H22 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $45.3 | $43.7 | $1.5 | 3.5% |
| OUS | $71.1 | $64.0 | $7.1 | 11.1% |
| EMEA | $34.9 | $30.4 | $4.6 | 15% |
| APAC | $27.5 | $24.6 | $2.9 | 11.9% |
| ROW | $8.7 | $9.0 | ($0.4) | (4.2%) |
| Total | $116.4 | $107.7 | $8.6 | 8% |
MicroPort Orthopedics reported 1H23 orthopedic sales of $116.4 million, +8% compared to the first half of 2022.
The company's efforts in expanding its channels in the EMEA region led to significant strength there, with mid-teens growth compared to the prior year. MicroPort's Medial-Pivot Knee made further inroads in international markets,...
MicroPort Orthopedics reported 1H23 orthopedic sales of $116.4 million, +8% compared to the first half of 2022.
The company’s efforts in expanding its channels in the EMEA region led to significant strength there, with mid-teens growth compared to the prior year. MicroPort’s Medial-Pivot Knee made further inroads in international markets, helping drive the company’s knee replacement sales.
MicroPort actively sought out secondary supply partners during the first half to mitigate future supply risks. The company received its first batch of components from those suppliers in July 2023, helping to reduce backorders significantly.
In its Chinese domestic market, the company drove growth greater than 50% driven by the implementation of volume-based procurement for joint replacement products and recovery in elective surgery demand. MicroPort is focused on reducing costs and increasing efficiency in its spine and trauma businesses as volume-based procurement tenders impact those segments.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. We estimate orthopedic sales and growth on an as-reported basis.
Orthopedic Sales by Segment
| 1H23 | 1H22 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $112.7 | $104.4 | $8.3 | 8% |
| Knees | $47.1 | $41.9 | $5.2 | 12.5% |
| Hips | $65.6 | $62.5 | $3.1 | 5% |
| Spine | $1.9 | $1.7 | $0.1 | 8% |
| Trauma | $1.8 | $1.6 | $0.2 | 11.6% |
| Total | $116.4 | $107.7 | $8.6 | 8% |
Orthopedic Sales by Geography
| 1H22 | 1H22 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $45.3 | $43.7 | $1.5 | 3.5% |
| OUS | $71.1 | $64.0 | $7.1 | 11.1% |
| EMEA | $34.9 | $30.4 | $4.6 | 15% |
| APAC | $27.5 | $24.6 | $2.9 | 11.9% |
| ROW | $8.7 | $9.0 | ($0.4) | (4.2%) |
| Total | $116.4 | $107.7 | $8.6 | 8% |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
